Liquidia (NASDAQ:LQDA) CFO Michael Kaseta Sells 20,430 Shares

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 20,430 shares of the business’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $1,460,949.30. Following the transaction, the chief financial officer directly owned 345,805 shares of the company’s stock, valued at $24,728,515.55. The trade was a 5.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Kaseta also recently made the following trade(s):

• On Wednesday, April 15th, Michael Kaseta sold 139,390 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total transaction of $5,595,114.60.

Liquidia Trading Up 7.4%

Shares of Liquidia stock opened at $76.49 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a 1 year low of $14.04 and a 1 year high of $82.96. The firm has a market cap of $6.80 billion, a PE ratio of 546.40 and a beta of 0.55. The company has a 50 day simple moving average of $66.37 and a two-hundred day simple moving average of $47.52.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s revenue was up 4187.1% compared to the same quarter last year. Analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Handelsbanken Fonder AB bought a new stake in shares of Liquidia in the 2nd quarter valued at about $1,993,000. Fulcrum Equity Management bought a new position in Liquidia during the 2nd quarter worth approximately $399,000. Fluent Financial LLC purchased a new position in Liquidia in the 2nd quarter worth approximately $287,000. FNY Investment Advisers LLC purchased a new position in Liquidia in the 2nd quarter worth approximately $1,395,000. Finally, Seven Fleet Capital Management LP lifted its position in Liquidia by 124.5% in the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after purchasing an additional 113,609 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LQDA. Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Oppenheimer set a $75.00 price objective on Liquidia in a report on Friday, June 5th. Bank of America reissued a “neutral” rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).